Company / Depreciation & Amortization
Arcutis Biotherapeutics, Inc. Depreciation & Amortization History
FY2018-FY2023 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Depreciation & Amortization
$800.0K
FY2023
5-year range
$454.0K / $800.0K
FY2019-FY2023
Trend
+28.6%
vs FY2022
Sector context
#127 of 163
Health Care
What the data says
Arcutis Biotherapeutics, Inc.'s depreciation & amortization of $800,000 is lower than 78% of companies in the Health Care sector (FY2023). Depreciation & Amortization has increased for 5 consecutive years, from $0 in FY2018 to $800,000 in FY2023.
Based on SEC 10-K filings.
$800,000 in FY2023 with a 3-year CAGR of +87.2%.
Increased from $454,000 to $800,000 over the past 2 years.
Health Care sector context is included.
Depreciation & Amortization over time
Growth rates
- 3-Year CAGR
- +87.2%
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Sector benchmark
-99.6% below sector average
Key checks
Key Insights
- Arcutis Biotherapeutics, Inc.'s depreciation & amortization has grown for 4 consecutive years.
- 3-year CAGR of +87.2%, indicating consistent growth.
- In FY2023, depreciation & amortization increased 28.6% year-over-year.
- Ranks #127 out of 163 companies in the Health Care sector.
Company context
Key Data Points
- Altman Z-Score -0.65 (distress zone, below 1.8 threshold)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Depreciation & AmortizationValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | - | - |
| FY2024 | - | - |
| FY2023 | $800.0K | +28.6% |
| FY2022 | $622.0K | +37.0% |
| FY2021 | $454.0K | +272.1% |
| FY2020 | $122.0K | +79.4% |
| FY2019 | $68.0K | - |
| FY2018 | $0 | - |
As of FY2023 · SEC 10-K · Updated Feb 28, 2026